Articles tagged with Schizophrenia
Researchers found that patients taking newer antipsychotics had less than one-third the incidence of violent behavior compared to those on older conventional medications. The study, which followed 229 patients with schizophrenia for two years, suggests that these medications may be more effective in reducing violence.
A new study found that only 41% of schizophrenia patients take their antipsychotic medication on a regular basis. Non-adherence is linked to higher medical costs and hospitalizations, with African-Americans and Latino patients more likely to be non-adherent than Caucasians. Living independently or being homeless are also associated wit...
Researchers found a moderate link between celiac disease and schizophrenia, with individuals having celiac disease three times more likely to develop the condition. A gluten-free diet may be beneficial for those genetically prone to celiac disease but undiagnosed, according to lead author Dr. William W. Eaton.
A two-year study found that quetiapine treatment resulted in statistically significant improvements in positive, negative and depressive symptoms. Patients also showed notable enhancements in quality of life, with minimal reported side effects.
Studies find that prenatal exposure to lead, alcohol, and anesthetic drugs can cause brain damage in young adults. Research suggests that these substances trigger apoptosis, a form of cell death, by interfering with neural connections.
A Swedish study found that risperidone long-acting injection reduced hospital admissions by 23% and mean hospital stay duration by 35%. This results in significant cost savings for the healthcare system, with estimates suggesting up to €6,300 per patient annually.
A new study demonstrates the benefits of Risperdal Consta in young adults with schizophrenia, improving symptoms and reducing side effects. The treatment showed significant satisfaction and improvement in health-related quality of life, making it a promising option for patients.
A new study explores the potential of erythropoietin (EPO) as a neuroprotective agent for schizophrenia. EPO was found to penetrate the blood-brain barrier and enhance cognitive functioning in patients with schizophrenia. The results suggest that EPO may be a promising compound for preventing loss of brain function in this disease.
Researchers used DTI to study adolescents with early-onset schizophrenia and found distinct differences in white brain matter of the frontal lobe. This disruption can lead to developmental abnormalities and abnormal behaviors.
A randomized, double-blinded study found no differences between olanzapine and haloperidol in reducing schizophrenia symptoms or improving quality of life. Olanzapine was associated with higher costs due to its high price tag, despite slightly better cognitive status and less restlessness.
Researchers discover that DARPP-32 interacts with multiple neurotransmitter systems to produce similar physiological symptoms in mice treated with LSD, PCP, and amphetamine. The findings provide new avenues for treating schizophrenia and suggest DARPP-32 as a critical regulator of neurotransmitters involved in mood and behavior.
A study found individuals at ultra-high risk for psychosis had difficulty identifying smells before symptom onset. This discovery could lead to a new diagnostic tool and earlier treatment options for schizophrenia and other psychoses.
A four-year study found that Risperdal significantly reduces the risk of relapse in schizophrenia patients, with a 42% lower rate compared to haloperidol. Patients taking Risperdal remained relapse-free for an average of over 15 months, whereas those on haloperidol were free for only seven months.
A new study shows significant improvements in positive and negative symptoms of schizophrenia when patients are switched to Risperdal Consta without a three-week overlap treatment period. The study found that side effects were mild to moderate, with extrapyramidal symptoms improving significantly by the first month.
A collaborative study between UGA and MCG investigated the cognitive effects of long-term use of newer schizophrenia drugs. The researchers found that while atypical antipsychotics cause fewer problems with movement disorders, their long-term impact on cognitive function is still unclear.
Studies suggest schizophrenia and bipolar disorder have reduced expression of genes responsible for myelin development in brain cells, potentially linked to environmental issues or infections. This discovery may enable early treatment before symptoms emerge in late adolescence or early adulthood.
Research suggests that schizophrenia and bipolar disorder share similar genetic causes, with key oligodendrocyte-related and myelin-related genes showing reduced expression in patients. This finding has implications for understanding the underlying mechanisms of these complex mental health conditions.
Research suggests that schizophrenia impairs habitual prospective memory, leading to high rates of non-adherence to medication. The study found that people with schizophrenia are more likely to forget to turn over a counter during an obstacle course test.
Researchers identify key genes and cellular pathways contributing to schizophrenia, providing new insights into the disorder's complex biology. The study's findings hold promise for developing novel therapeutic strategies.
Researchers have identified a genetic variant in the calcineurin pathway that may be linked to schizophrenia. The study found that mice lacking this gene exhibited severe behavioral abnormalities similar to those seen in humans with the disorder, including hyperactivity and social withdrawal.
A study using PET scans found that schizophrenics have elevated dopamine receptor levels in both basal forebrain and SN/VTA areas of the brain. Differences were observed in cortical dopamine levels, supporting the hypothesis of dysregulated neurotransmission leading to abnormal regulation of neurons.
A team of researchers discovered a genetic break in human chromosome 14 affecting brain development and behavior. The broken gene may contribute to mental illness, including schizophrenia, in affected families. The study provides a crucial piece of the puzzle in understanding the complex disease.
Research supports the hypothesis that mesocortical dopamine function is impaired in schizophrenia, with decreased D2/3 receptor density associated with negative and general psychopathological symptoms. Age was also negatively correlated with D2/3 receptor density among controls.
A study found that a specific gene variant affects prefrontal brain function and response to amphetamine. People with the val/val variant had reduced prefrontal dopamine activity and less efficient information processing, while those with met/met had more efficient function but also faced cognitive decline when challenged.
A study published in the American Journal of Human Genetics has identified two overlapping genes on chromosome 13 as increasing susceptibility to bipolar disorder, affecting 2 million Americans. The same gene complex is also linked to an increased risk for schizophrenia.
A new virtual reality device re-creates hallucinations associated with schizophrenia, helping patients better understand their condition and adhere to medication. The technology also offers healthcare professionals a tool to assess treatment effectiveness, ultimately improving patient outcomes.
Researchers studied 65 families with bipolar disorder and found strong genetic 'linkage' to specific regions on chromosomes 13 and 22, suggesting common genes contributing to both bipolar disorder and schizophrenia. These overlap genes may explain why the same anti-psychotic medications are effective treatments for both diseases.
A study found that patients with schizophrenia experienced improved symptom management and reduced side effects when switching to Seroquel, including significant reductions in Positive and Negative Syndrome Scale scores and Clinical Global Impression Severity of Illness ratings.
Research suggests that postnatal experiences can affect brain development and function in individuals with Fragile X syndrome, a genetic disorder causing mental retardation, and schizophrenia, a severe emotional disorder. Abnormalities in synaptic pruning processes and neurotransmitter regulation are common to both conditions.
Researchers describe groundbreaking cognitive therapy approach that helps people with schizophrenia identify and challenge negative thoughts, leading to significant symptom reductions. The therapy, combined with medication, offers hope for those who have not responded to traditional treatments.
Researchers found that bupropion significantly reduced negative symptoms of schizophrenia, improving motivation and social relationships, while also aiding in nicotine addiction treatment for schizophrenic patients. The study showed better smoking cessation outcomes with newer atypical antipsychotic medications.
A new study found that combination therapy with divalproex can significantly reduce schizophrenia symptoms, even as early as the third day of treatment. The study showed that patients treated with the combination had better outcomes than those receiving antipsychotic drugs alone.
A new study by UCLA researchers found that Rh-incompatible mothers are more than twice as likely to have children with schizophrenia. The study mapped genetic data from 181 Finnish families and discovered a significant link between the RHD gene and schizophrenia risk.
A study found that an uncommon variation of the Nogo gene increases schizophrenia risk, particularly when inherited from both parents. One in five people with schizophrenia has this risk gene, and researchers hope to discover new related genes to aid diagnosis and treatment.
A nationwide brain imaging network will share data from patients with schizophrenia to expand understanding of the disease and develop new treatments. The project, led by Steven G. Potkin, aims to create a comprehensive database of brain images and advance research in brain disorders.
Researchers found three distinct clusters of patients with different memory and brain profile patterns, suggesting multiple disease mechanisms. The 'cortical' subtype showed temporal lobe pathology, while the 'subcortical' subtype featured frontal-striatal region issues.
The UNC Conte Center will conduct four interrelated studies using distinct research methods to identify critical brain events triggering the development of psychotic symptoms in schizophrenia. The center aims to explain how certain behavioral and neurobiological factors transform normal individuals into those with schizophrenia.
A recent study by Dr. Gus Thompson found that Canadians, particularly Albertans, attribute schizophrenia to genetic factors and biochemical imbalances. Although stigma remains, the study shows a positive shift in perceptions towards mental illness over the past few decades.
A genetic study in Palau reveals distinct genetic factors contributing to schizophrenia in each of five families. The findings reinforce the complexity of schizophrenia and demonstrate the value of large extended pedigrees for gene mapping.
A study by UCI researchers found lower levels of DARPP-32, a key regulatory protein, in the brains of people with schizophrenia. This reduction may contribute to cognitive dysfunction and social problems associated with the disease.
Researchers propose that schizophrenia may be triggered by an interaction between genes and viruses in glial cells, which can disrupt brain cell connections. This new hypothesis combines previous theories on the disease's causes, offering a potential explanation for its development.
A study found that certain alleles or genotypes of the CNR1 gene may confer a susceptibility to schizophrenia, especially of the hebephrenic type. The presence of specific polymorphisms in the CNR1 gene was significantly associated with an increased risk of developing schizophrenia.
Brain scans reveal abnormal brain structure and function at an early stage, suggesting a powerful predictor of future illness. This finding may enable treatment to prevent distressing symptoms like hallucinations from developing.
Scientists conducted a study on genetic markers in families with multiple members diagnosed with schizophrenia, finding potential associations on chromosome 1q. However, these genes are thought to influence only a small proportion of patients, highlighting the complexity of unraveling complex diseases.
Researchers found late-onset schizophrenia to be a distinct condition characterized by tau protein abnormalities. The study analyzed brain tissue from patients and found that changes in the hippocampus were caused by hyper-phosphorylation of tau.
Human neural stem cells transplanted into normal mice and reeler mice showed symmetrical migration in the former but failed to migrate in the latter. This suggests that protein reelin plays a critical role in directing stem cell migration, potentially underlying schizophrenia's distorted perception and thinking.
Researchers have linked two key brain abnormalities in schizophrenia, including reduced frontal lobe activation and abnormal dopamine release, suggesting a common pathophysiological mechanism. The study suggests that antipsychotic drugs may target the wrong area, leading to an excess of dopamine activity.
A new study found that risperidone, a second-generation antipsychotic medication, cuts the one-year rate of relapse for patients with schizophrenia in half compared to haloperidol. This reduction could have significant economic benefits and improve patient outcomes.
A large-scale study has identified genetic links to schizophrenia in European-American and African-American families. The research found a positive association between chromosome 15 and schizophrenia in European-Americans, but no such link in African-Americans.
Scientists at UCLA and NIMH detected a spreading wave of gray matter loss in schizophrenic patients, which engulfed the brain over five years, leading to worse symptoms. The study's findings may aid early detection and treatment, as well as inform future medication development.
A new report reveals that bipolar disorder costs the UK over £2 billion annually, with up to 85% associated with lost productivity. The study suggests Risperdal as an effective treatment for acute bipolar mania, improving symptoms by at least 50% in patients.
Researchers propose a blood test to diagnose schizophrenia by measuring the levels of mRNA molecules encoding D3 dopamine receptors on white blood cells. This test may help assess the biological basis of the disease, which is still unknown.
A new brain imaging study found the thalamus, a key sensory filter, is smaller than normal in people with schizophrenia from its earliest stages. This may explain why individuals experience confusion during their illness due to impaired information processing and overload in certain brain regions.
A recent study found that newer anti-psychotic drugs like clozapine are more effective in treating first-time schizophrenia patients than traditional medications. The research also suggests a potential link between toxoplasmosis and poorer treatment outcomes.
A new study from the Institute of Psychiatry finds that schizophrenia affects carers' mental and physical well-being from its earliest stages. Carers experience distress due to difficult behaviors and social withdrawal, emphasizing the importance of providing support to prevent further mental illnesses.
A new study reveals that brain function differences in people with schizophrenia make it hard for them to understand and empathize with others. This can lead to problems in relating to people, making friends and getting jobs, which may contribute to rare incidents of violence.
A Yale study shows that combining newer antipsychotic drugs with a nicotine patch leads to nearly triple the success rate in quitting smoking for schizophrenic patients. The study found that this combination was particularly effective in reducing carbon monoxide levels, a by-product of cigarette smoke.
A new brain imaging study found that people with schizophrenia exhibit distinct brain changes at the earliest stages of the illness, potentially identifying warning signs and preventing development. The research suggests a role for brain imaging in pinpointing early signs and may lead to preventive psychiatry.
A new study published at the CINP meeting found that treating patients with schizophrenia with Risperdal resulted in a daily savings of $2.80 US per patient, corresponding to an annual saving of $1,022 US. This cost-effectiveness analysis may translate into significant figures given the high prevalence of schizophrenia worldwide.
A new 25-minute test distinguishes between different types of schizophrenia by measuring people's response to a sudden loud noise. Early onset schizophrenia has more severe information processing deficits and is less responsive to current treatments.